Licensing Opportunities

Lexaria Bioscience Corp’s disruptive new patented technology DehydraTECH™ is available to be licensed by both the consumer packaged goods industry as well as the drug and pharmaceutical industry. Product formulations designed for oral delivery or for topical (skin-based) delivery are currently available.

DehydraTECH can be used to improve existing products or to create new products. It is suitable for use with a wide range of consumer product formats including:

  • Registered Drugs
  • Nutraceuticals
  • Consumer Packaged Goods
  • Capsules, Pills and Tablets
  • Oral Suspsensions
  • Topical Applications

Testing DehydraTECH™ in the Real World

DehydraTECH is designed to be effective in delivering most fat-soluble molecules through the human gastrointestinal system and has also demonstrated affinity for transdermal applications and even effectiveness in crossing the blood-brain-barrier once within blood plasma. Lexaria has, or is conducting, in vitro, in vivo and human clinical testing, including pharmacokinetic data gathering, for the delivery of API’s through ingestible means. Test data has consistently pointed to reduced time required to enter the bloodstream, increased absorption rate, and reported improvements in taste and smell of edible products.

Contact us today to speak about your licensing needs at [email protected]

Terms and rights associated with our licensing opportunities are discussed on an individual basis.

Partnering with Industry Experts to Implement DehydraTECH Across Many Fields

Lexaria’s typical approach to working with a new prospective licensee is to effect confidentiality terms and then collaborate with the license prospect under a non-binding letter of intent to evaluate the feasibility and applicability of the Lexaria DehydraTECH technology for the license prospect`s needs.  Following this, if the license prospect is satisfied with the performance enhancements delivered by the DehydraTECH technology, Lexaria then seeks to transition to a definitive fee bearing agreement structure between it and the new licensee.

We will license our technology to companies operating in any of the more than 40 countries around the world where the DehydraTECH is patented or patent-pending. Licensees can feel confident that Lexaria’s extensive IP portfolio – constantly expanding – will help to provide a competitive edge and protection against inferior methodologies or older, outdated technology.  Also, licensees benefit from the fact that Lexaria’s research team is constantly innovating and developing next generation enhancements and additions to its technology portfolio which it makes available to them as needed.

If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application. DehydraTECH is compatible with many other processes.

A Cost-Effective Measure to Improve Consumer Experiences & Bioavailability

Licensees should also always remember that DehydraTECH costs less than a penny per serving to implement – sometimes a bare fraction of a penny. Capex for necessary equipment is also low and many existing production facilities will already have sufficient existing equipment that may be able to be repurposed.

Licensees may experience an increase in market share or an increase in pricing power as a result of offering their customers superior delivery characteristics and product performance. Customers are loyal to the improved performance of DehydraTECH based products.

DehydraTECH is one of the world’s ONLY delivery technologies that does not require the addition of complex chemicals or ingredients requiring disclosure on a food label. DehydraTECH works with commons GRAS ingredients that can be organic, vegan, gluten-free, and dairy free.

If your company works in a different but related field, please contact us if you’d like to conduct research on applicability for your specific application.

Our proprietary technology delivers several important benefits

Reduces time of onset

Many prescription drugs and active ingredients require 60-120 minutes to transit the stomach, intestine and liver on their journey to the bloodstream. DehydraTECH reduces this time of onset to just minutes; tested and validated at between 10  – 30 minutes typically, and in some cases with onset possible in as little as 1.5-4.0 minutes.

Increases bio-absorption

Increases bio-absorption to the bloodstream by 100 – 500%, typically, and across the blood brain barrier in repeated animal tests of up to 1,900%. These dramatic efficiency improvements open new possibilities for classes of drugs such as antiviral, non-combusted nicotine and more.

Masks taste/odor

Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners. For consumer packaged goods, the avoidance of artificial or excessive sweeteners or flavoring agents can have a major impact to consumer acceptance.

Avoids first-pass liver metabolism

Testing has evidenced that DehydraTECH may deliver molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects.In a human clinical study, Lexaria confirmed that liver metabolites of the active ingredient tested were lower than in the positive control, indirectly supporting this hypothesis.

Contact Us

Contact Lexaria’s Sales Team at [email protected] to discuss your licensing needs.